PTPoonam Thakur

Poonam Thakur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Poonam Thakur has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chlorogenic acid fails to confer neuroprotection in a chronic mouse model of Parkinson’s disease

    by Akshaya Rajan, Surya Prakash, Devendra Singh, Poonam Thakur

    Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by α-Synuclein (α-Syn) aggregation, dopaminergic neuronal loss, and chronic neuroinflammation. Chlorogenic acid (CA), a dietary polyphenol abundant in coffee, exhibits antioxidant and anti-inflammatory properties and has shown neuroprotective effects in acute toxin-based PD models. However, its efficacy in chronic, α-Syn–driven PD models remains unclear. Here, we evaluated the therapeutic potential of CA using an α-Syn–based in vitro system and a chronic α-Syn overexpression mouse model that recapitulates key pathological features of human PD. In vitro , CA significantly improved cell viability, reduced α-Syn aggregation, and attenuated H 2 O 2 -induced apoptosis in U118 and N2a cells. In contrast, chronic oral administration of CA (100 mg/kg for 16 weeks) in C57BL/6J mice (male and female) failed to improve motor behavior, attenuate α-Syn pathology, preserve nigrostriatal dopaminergic neurons, or reduce oxidative stress–associated DNA double-strand breaks in vivo . Notably, CA elicited a modest reduction in microglial and astrocytic activation in female mice, highlighting a sex-dependent immunomodulatory response. Collectively, these findings reveal a clear dissociation between robust in vitro neuroprotection and limited in vivo efficacy in a chronic α-Syn–driven PD mouse model, emphasizing the importance of incorporating progressive disease paradigms and sex as a biological variable in preclinical therapeutic evaluation.

  • Open Access

    Integrative lipidomics of brain and plasma uncovers sex-specific metabolic signatures in Parkinson’s disease

    by Unnati Agrawal, Priya Nataraj, Aakash Chandramouli, Syam Krishnan, Siddhesh S. Kamat, Madhusoodanan Urulangodi, Poonam Thakur

    Lipid dysregulation is increasingly recognized as a key feature of Parkinson’s disease (PD). A central unresolved question, however, is whether lipidomic signatures identified in accessible peripheral biofluids faithfully recapitulate the pathogenic alterations within the central nervous system (CNS). This gap impedes the development of reliable biomarkers and constrains a comprehensive understanding of PD pathophysiology. To address this challenge, we employed a cross-species lipidomic approach. We modeled PD in both male and female mice by injecting human α-synuclein preformed fibrils into the substantia nigra. Three months post-injection, lipidomic profiles of the midbrain and plasma were generated and compared. These findings were further validated in plasma from male and female PD patients and age-matched controls, enabling the identification of conserved alterations. We identified shared dysregulation of sphingolipids, glycerophospholipids, and fatty acids in the brains and plasma of diseased mice as well as in plasma from PD patients. Notably, lipids associated with lipid droplet biogenesis, including triacylglycerols and monoacylglycerols, were elevated in diseased mouse brains and patient plasma. These alterations coincided with a marked accumulation of lipid droplets in the mouse midbrain, and were further corroborated by increased lipid droplet abundance in macrophages derived from PD patients. Interestingly, lipid droplet accumulation exhibited sex-specific patterns: male mice displayed greater microglial accumulation, whereas female mice showed enhanced neuronal deposition. Together, these findings demonstrate that peripheral lipidomic signatures reflect CNS pathology in PD, highlighting new opportunities for biomarker discovery and therapeutic intervention. Furthermore, sex-specific lipid droplet accumulation in innate immune cells and neurons implicates these pathways as mechanistic contributors to PD and underscores the necessity of sex-stratified strategies in biomarker discovery and disease modeling.

  • Glycated Alpha-Synuclein Assemblies Cause Distinct Parkinson’s Disease Pathogenesis in Mice

    by Akshaya Rajan, Anish Varghese, Shaliya Puthanveedu Hashardeen, Ann Teres Babu, Vinesh Vijayan, Poonam Thakur

    Alpha-synuclein (α-Syn) misfolding and aggregation are key drivers of Parkinson's disease (PD) pathology. Mutations and certain post-translational modifications impact its aggregation propensity and pathogenicity. Glycation, a nonenzymatic modification enhanced during hyperglycemia and aging, both known risk factors for PD, has been implicated in α-Syn pathology. Although preformed α-Syn fibrils induce PD-like phenotypes in mice, the impact of glycation on their pathogenicity is unclear. In the current study, we glycated α-Syn using methylglyoxal (MGO), a potent glycating agent, resulting in altered biophysical characteristics in comparison to nonglycated α-Syn. Glycation inhibited the formation of typical β sheet structures under aggregating conditions. Despite that, glycated α-Syn assemblies induced dopaminergic neurodegeneration and neuroinflammation to a similar extent as the nonglycated α-Syn fibrils upon their injection in the mouse substantia nigra (SN). However, these glycated assemblies triggered higher neuroinflammation and increased accumulation of receptor for advanced glycation end products (RAGE) compared to nonglycated fibrils. Consequently, an earlier onset of neuromuscular deficits and anxiety was observed in these mice. Thus, glycation of α-Syn causes distinct PD-associated pathology compared to nonglycated α-Syn, causing an earlier onset of motor symptoms. These findings provide insight into how the glycation of α-Syn due to hyperglycemia may contribute to an increased risk of PD in diabetic populations.


  • Open Access

    Glycated alpha-synuclein assemblies cause distinct Parkinson’s disease pathogenesis in mice

    by Akshaya Rajan, Anish Varghese, Shaliya Puthanveedu Hashardeen, Ann Teres Babu, Vinesh Vijayan, Poonam Thakur

    Alpha-synuclein (α-Syn) misfolding and aggregation are key drivers of Parkinson’s disease (PD) pathology. Mutations and certain post-translational modifications impact its aggregation propensity and pathogenicity. Glycation, a non-enzymatic modification enhanced during hyperglycemia and aging, both known risk factors for PD, has been implicated in α-Syn pathology. Although preformed α-Syn-fibrils induce PD-like phenotypes in mice, the impact of glycation on their pathogenicity is unclear. In the current study, we glycated α-Syn using methylglyoxal (MGO), a potent glycating agent, resulting in altered biophysical characteristics in comparison to non-glycated α-Syn. Glycation inhibited the formation of typical beta sheet structures under aggregating conditions. Despite that, glycated α-Syn assemblies induced dopaminergic neurodegeneration and neuroinflammation to a similar extent as the non-glycated α-Syn fibrils upon their injection in the mouse substantia nigra (SN). However, these glycated assemblies triggered higher neuroinflammation and increased accumulation of receptors for advanced glycation end products (RAGE) compared to non-glycated fibrils. Consequently, an earlier onset of neuromuscular deficits and anxiety was observed in these mice. Thus, glycation of α-Syn causes distinct PD-associated pathology compared to non-glycated α-Syn, causing an earlier onset of motor symptoms. These findings provide insight into how glycation of α-Syn due to hyperglycemia may contribute to an increased risk of PD in diabetic populations.

  • Open Access

    Editorial: Glial cells in health and disease: impacts on neural circuits and plasticity

    by Shirin Hosseini, Poonam Thakur, David L. Cedeno, Masoud Fereidoni, Mahmoud Elahdadi Salmani

    This research topic has markedly enhanced the current understanding of the role of glial cells on pathological conditions of both the central nervous system (CNS) and peripheral nervous system (PNS) (Verkhratsky et al., 2014; Tan et al. 2021). The diversity of these conditions is largely dictated by glial cells in the particular regions of the affected neural tissue and the distinct interactions of glial cells and other cells. Investigating the common molecular mechanisms underlying these conditions can illuminate pathways for developing innovative therapeutic strategies.This comprehensive analysis synthesizes findings from the pivotal studies in this research topic, highlighting critical intersections between neuroimmunology and cellular neurophysiology. The study of Kleidonas et al. delineates the acute effects of elevated ammonia levels, relevant to liver dysfunction, on the synaptic transmission of CA1 neurons in mouse entorhino-hippocampus tissue. Elevated ammonia suppresses neuronal action due to their impact on astrocyte functionality, highlighting the key regulatory role that astrocytes play in maintaining synaptic homeostasis, through modulating excitatory synapses. Importantly, it was observed that the inhibition of glutamine synthetase, an astrocytic enzyme, mitigates the downregulation of excitatory transmissions, reinforcing the pivotal role of astrocytes in neural function.Concurrently, the study by Gabele et al. delves into the sex-specific neurotropic effects of influenza A virus (H7N7 strain) on mouse hippocampal cells. It unveils that female-derived cells exhibit a more pronounced innate immune response, marked by elevated interferon-β and chemokine secretion, leading to differential microglial activation and morphological neural changes compared to male-derived cells. This sex-specific variation in immune response highlights the intricate dynamics of pathogen or stressor-host interactions within the CNS, which warrants careful consideration of sex-specific effect in future research endeavors (Chen et al., 2018).The review study by Kveštak et al. extends the discussion to Innate Lymphoid Cells (ILCs), which, although a minor component of the CNS under physiological conditions, infiltrate CNS parenchyma during neuroinflammatory and infectious scenarios. ILCs, through interactions with other immune cells, including astrocytes and microglia, modulate CNS tissue responses, thereby influencing the outcomes of autoimmune diseases and viral infections. This understanding of ILC function aligns with the findings of the previous two studies suggesting potential synergistic effects between cellular stress responses of peripheral immune system and immune modulation in the CNS.The interactions between glial cells and neurons in the PNS play a critical role alongside those in the CNS (Müller et al., 2025). The study of Mohamed et al. enhances our understanding of the multifaceted roles of protein kinase C epsilon type (PKCε) within the PNS. While PKCε is already recognized for its involvement in cancer progression, this study uncovers a novel function in Schwann cells (SCs), the glial cells of the PNS, which are crucial for peripheral nerve regeneration and functionality. This work elucidates the capacity of PKCε to modulate SCs proliferation, migration, and differentiation, highlighting its role in facilitating the transition between proliferative and differentiated states, as well as an epithelial-mesenchymal transition-like process. The identification of a BDNF-TrkB-PKCε autocrine signaling axis provides valuable insights into the molecular mechanisms regulating SCs plasticity. This groundbreaking work suggests that targeting this pathway may open new therapeutic avenues for addressing peripheral nerve injuries, neuropathic pain, peripheral nerve tumors, and related neuropathies, thereby broadening the scope for intervention in PNS-related disorders.In the work conducted by Schröder et al. a rational drug design approach was employed to address Multiple Sclerosis (MS), a chronic, autoimmune, demyelinating disease of the CNS; although clinical studies have demonstrated PNS involvement in a subgroup of patients (Adamec et al., 2021). The study focused on polysialic acid (polySia), a glycan recognized for its immunomodulatory properties, demonstrating its potential benefits in the upregulation of myelin. Notably, the application of polySia with a chain length of DP24–30 in organotypic murine brain slices was found to significantly enhance remyelination. This effect is mediated through the modulation of microglial activation via the inhibitory immune receptor Siglec-E. Furthermore, the findings indicate that polySia effectively reduces proinflammatory responses in microglia, fostering an environment that supports myelin regeneration. By elucidating the immunomodulatory and pro-regenerative capabilities of polySia, this study contributes to a deeper understanding of the mechanisms underlying myelin repair, establishing polySia as a promising therapeutic target for treating demyelinating diseases such as MS.Remarkably, the investigation of polySia on SCs is particularly intriguing, as polySia has been shown to enhance SCs proliferation and migration, thereby promoting peripheral nerve regeneration and myelination, which could offer novel therapeutic insights for neuropathic conditions and nerve injuries.In the mini-review by Gjervan et al., an alternative strategy for myelin repair is presented, focusing on claudin-11, a crucial protein of tight junctions within the myelin sheath. Recent studies have elucidated that heterozygous stop-loss mutations in the CLDN11 gene are implicated in the etiology of hypomyelinating leukodystrophy 22 (HLD22), a genetic disorder characterized by impaired myelination. Investigations conducted in claudin-11-deficient mouse models have demonstrated significant physiological impairments, including delayed...


  • Open Access

    A Novel Mouse Model of Parkinson’s Disease for Investigating Progressive Pathology and Neuroprotection

    by Santhosh Kumar Subramanya, Shreshth Shekhar, Devu B Kumar, Sathyapriya Senthil, Dharmaraja Allimuthu, Kelvin C Luk, Poonam Thakur

    Developing animal models that successfully recapitulate the features of progressive Parkinson’s disease (PD) is crucial for understanding disease progression mechanisms and creating effective therapeutic interventions. In this study, we created a mouse model of PD by overexpressing α-synuclein through a combined injection of AAV6-α-synuclein and preformed fibrils (PFFs) into the medial and lateral substantia nigra (SN). We also demonstrated that chronic administration of the c-Abl inhibitor PD180970 provides neuroprotection in this model. Mice injected with the AAV6-α-synuclein and PFF combination showed a progressive loss of dopaminergic (DA) neurons in the SN and their projections in the striatum over 24 weeks. This neuronal loss coincided with a time-dependent accumulation of phosphorylated α-synuclein (p-syn) in the SN. The p-syn aggregates spread to synaptically connected DARPP-32-positive neurons in the striatum and further extended to the cortex. We also observed a contralateral spread of p-syn aggregates. Additionally, α-synuclein overexpression led to a significant increase in activated microglia and astrocytes at all timepoints, with the strongest activation occurring early and gradually diminishing over time. Daily administration of PD180970 significantly reduced the loss of DA neurons caused by α-synuclein injection and decreased the accumulation of p-syn in the SN. PD180970 treatment also reduced the neuroinflammation significantly. Overall, the combined injection of AAV6-α-synuclein and preformed fibrils into the mouse brain establishes a robust PD model, enabling detailed mechanistic studies of the disease. We further demonstrate the model’s utility for chronic neuroprotection studies using the potential drug PD180970, highlighting its broad applicability. Significance Statement: This study establishes a robust mouse model of Parkinson’s disease (PD) by combining AAV6-mediated α-synuclein overexpression and preformed fibrils (PFFs) to replicate key features of PD, such as progressive dopaminergic neuron loss, phosphorylated α-synuclein accumulation, and neuroinflammation. The model captures the spread of pathological aggregates to synaptically connected brain regions, closely mimicking the human disease. By testing the c-Abl inhibitor PD180970, we demonstrate its neuroprotective effects, including reduced neuronal loss, decreased α-synuclein accumulation, and neuroinflammation highlighting its therapeutic potential. This model offers a valuable platform for investigating PD mechanisms and evaluating novel interventions, bridging the gap between preclinical and clinical applications.


  • Open Access

    A One-Step Mouse Model of Parkinson’s Disease Combining rAAV-α-Synuclein and Preformed Fibrils of α-Synuclein

    by Santhosh Kumar Subramanya, Devendra Singh, Poonam Thakur

    Developing preclinical animal models that faithfully mimic the progressive nature of Parkinson’s disease (PD) is crucial for advancing mechanistic insights as well as therapeutic discovery. While recombinant adeno-associated virus (rAAV)-driven α-synuclein overexpression is widely used, its reliance on high viral titers introduces nonspecific toxicity and limits physiological relevance. The SynFib model, which combines modest rAAV-driven α-synuclein expression (Syn) with α-synuclein preformed fibril (PFF) seeding (Fib), has shown promise in reproducing PD-like pathology. However, current implementations of this SynFib model have largely been confined to rats and require sequential surgeries, which increase animal distress and reduce reproducibility. Here, we present a streamlined protocol to generate a SynFib mouse model of PD that integrates rAAV-α-synuclein delivery and PFF injection into a single stereotaxic surgery. Using fine glass capillaries, this method prevents backflow of injected material, reduces injection-induced trauma, minimizes neuroinflammation, and ensures robust lesion development. This streamlined mouse model provides a reproducible and practical system to investigate α-synuclein-associated pathology and serves as a versatile platform for preclinical testing of potential therapeutics for PD.


  • Interaction of alpha-synuclein with lipids

    by Neha Kachappilly, Jyotirmay Srivastava, Bani Prasad Swain, Poonam Thakur